Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, ...

Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate prices concessions, Bloomberg reported. The company told USA TODAY that it would ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hospitalisations account for up to 70% of total healthcare costs for people with ... The new approval comes shortly after Jardiance became the first SGLT2 drug to be approved by the FDA in ...

Most notable is Eli Lilly/Boehringer’s Jardiance, which has broken new ground by being the first diabetes drug licensed to claim ... metformin combination will cost $3,263 a year, while ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

People with Medicare Part D plans shoulder a share of the cost of their prescription drugs. Under the standard Part D benefit ...

Concurrently, a preprint from the industry-backed Vital Transformation found a 50% drop in company investments into ...

A new study examining the use of high-cost drugs among patients with colorectal cancer and non-small cell lung cancer found ...

AARP’s new research finds price growth for top Part D prescription drugs has exceeded inflation, making a case for allowing ...

Top Medicare Part D drugs without price negotiations have seen a 98% increase in list prices since their launch. Read more ...